Novo Nordisk

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.

News

Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.

News

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.

News

Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes.

News

Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.